Idera Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1989-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.aceragen.com
Clinical Trials
31
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03865082
- Locations
- 🇺🇸
Banner University Medical Center Tucson Campus, Tucson, Arizona, United States
🇺🇸University of Southern California/ Hoag Hospital Presbyterian, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 481
- Registration Number
- NCT03445533
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Cancer Treatment Centers of America (CTCA) - Western Regional Medical Center, Scottsdale, Arizona, United States
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03052205
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California San Francisco (UCSF), San Francisco, California, United States
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02644967
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center Research Institute, Tampa, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Trial of IMO-8400 in Adult Patients With Dermatomyositis
- Conditions
- Dermatomyositis
- Interventions
- Drug: IMO-8400 Dose Group 1Drug: PlaceboDrug: IMO-8400 Dose Group 2
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02612857
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Neurological Associates, Phoenix, Arizona, United States
🇺🇸University of California, Irvine, Irvine, California, United States
- Prev
- 1
- 2
- 3
- Next